This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (361) Diabetes (234) Pilot studies (non-ehealth) (83) Chronic Conditions (357) Nephrology/Renal Disorders (85)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56067, first published .
Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)

Authors of this article:

Steffen Flindt Nielsen1, 2 Author Orcid Image ;   Camilla Lundgreen Duus1, 2 Author Orcid Image ;   Niels Henrik Buus2, 3 Author Orcid Image ;   Jesper Nørgaard Bech1, 2 Author Orcid Image ;   Frank Holden Mose1, 2 Author Orcid Image
Article Authors Cited by (5) Tweetations (3) Metrics

Journals

  1. Nielsen S, Duus C, Buus N, Bech J, Mose F. Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin. Kidney International Reports 2025;10(1):134 View
  2. Jensen M, Nielsen S, Thiel S, Hansen S, Palarasah Y, Svenningsen P, Bech J, Mose F, Jensen B. Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD. Kidney International Reports 2025;10(2):591 View
  3. Kristensen D, Mose F, Buus N, Duus C, Mårup F, Bech J, Nielsen S. SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial. Diabetes, Obesity and Metabolism 2025;27(3):1123 View
  4. Nielsen S, Duus C, Buus N, Bech J, Mose F. The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials. Journal of Hypertension 2025;43(6):1021 View
  5. Wang M, Zuo L. Cardiorenal Benefits of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Concomitant Hypertension. Cardiorenal Medicine 2025;15(1):496 View